Tibsovo

(ivosidenib)
ivosidenib 250 MG Oral Tablet [Tibsovo]

Dosage & administration

500 mg orally once daily with or without food until disease progression or unacceptable toxicity . Avoid a high-fat meal.

Most viewed Tibsovo resources

Enroll in Patient Savings Program

eficacy, safety & testing

Tibsovo clinical details

Efficacy: Acute Myeloid Leukemia (AML)
Safety Profile: Acute Myeloid Leukemia (AML)
Dosing & Administration: Acute Myeloid Leukemia (AML)
Mechanism of Action (MOA)
Biomarker & Genetic Testing: Acute Myeloid Leukemia (AML)
Efficacy: Cholangiocarcinoma (CCA)
Safety Profile: Cholangiocarcinoma (CCA)
Dosing & Administration: Cholangiocarcinoma (CCA)
Biomarker and Genetic Testing: Cholangiocarcinoma (CCA)

drug label

Tibsovo prescribing information

Have more Tibsovo questions?

Submit MSL Request
Learn More

Need to report a Tibsovo issue?

ONLINE FORM
Report adverse event
Learn More

samples

Request Tibsovo samples

NOT PROVIDED BY BRAND
Sample Request
Learn More

prior authorization

Tibsovo Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRAND
Coverage Authorization Request

NOT PROVIDED BY BRAND
Complete Coverage Authorization appeals
Coverage Authorization Appeal
Learn More

Benefits investigation

Servier One Enrollment Form
Learn More

Reimbursement help (FRM)

NOT PROVIDED BY BRAND
Reimbursement help (FRM) resources
Learn More

financial assistance

Tibsovo Financial assistance options

Co-pay savings program

commercial only
Enroll in Patient Savings Program
Learn More

Bridge program

commercial only
Servier One Enrollment Form
Bridge Program - Max 2 Month Supply
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Servier One Enrollment Form
Patient Assistance Program
Learn More

patient education

Tibsovo Patient education

Getting started on Tibsovo

NOT PROVIDED BY BRAND
Instructions For Use: Acute Myeloid Leukemia (AML)

NOT PROVIDED BY BRAND
Instructions For Use: Cholangiocarcinoma (CCA)

Patient toolkit

Other Patient Resources - Servier ONE for Cholangiocarcinoma (CCA)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Acute Myeloid Leukemia (AML) Factsheet
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Cholangiocarcinoma (CCA) Factsheet
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Tibsovo: Acute Myeloid Leukemia (AML)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects: Acute Myeloid Leukemia (AML)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
View How to Take Tibsovo: Acute Myeloid Leukemia (AML)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources: Acute Myeloid Leukemia (AML)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure: Acute Myeloid Leukemia (AML)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Tibsovo: Cholangiocarcinoma (CCA)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects: Cholangiocarcinoma (CCA)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
View How to Take Tibsovo: Cholangiocarcinoma (CCA)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources: Cholangiocarcinoma (CCA)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure: Cholangiocarcinoma (CCA)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Tibsovo FAQs

FAQ Data Source

Can't find what you're looking for?

Our trained staff can help you:
Please note:
  • Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
  • Samples are provided at the discretion of the brand.
  • We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.